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TransplantatABSTRACT
Introduction. Cardiovascular disease is more common in renal transplant recipients
(RTRs) than in the general population, and is the major cause of both graft loss and patient
death in RTRs.
Objectives. This study aimed to characterize the cardiovascular risk factors, calculate the
7-year risk for major adverse cardiac events and the 7-year risk for death in a population of
RTRs using a cardiovascular risk calculator, and determine the main cardiovascular risk
factors associated with increased prediction of major adverse cardiac event (MACE) and
death.
Patients. This is a retrospective review of clinical data from 121 RTRs who are in follow-
up programs at our institution, and who had a functioning and stable graft for longer than 6
months.
Results. Among 121 adult patients followed at our institution (59.5% males, mean age of
49.6  13.8 years, mean times for functioning grafts were 105  73.5 mo), 86.8% had
hypertension, 19.8% had diabetes, 24.8% were current or former smokers, 61.9% had
increased body mass index, and 71% had dyslipidemia. The 7-year risk for MACE was
more than 10% in 38 (31.4%) patients with age, diabetes, and smoke being independent
risk predictors. The 7-year risk for death was more than 10% in 56 (46.3%) patients
with age, diabetes, blood pressure, smoking, and male gender being independent risk
predictors.
Conclusion. There is a high prevalence of cardiovascular risk factors in a population of
RTRs, and there is increased risk for MACE and death. Accurate risk prediction is
important for physician decision support and patient education, promoting improved
cardiovascular health of RTRs, and thus prolonging the survival of both patients and graft.*Address correspondence to Miguel Gonçalves, Department of
Nephrology, Hospital Central do Funchal, Avenida Luís de
Camões n57, 9004-514, Funchal, Portugal. E-mail: amvg.
leugim@gmail.comCARDIOVASCULAR DISEASES (CVDs) are theleading cause of morbidity and mortality in patients with
chronic renal disease [1,2]. Kidney transplantation, compared
to dialysis, promotes the reduction of cardiovascular risk [2,3].
However, the mortality rates due to CVD in kidney transplant
recipients (RTRs) are greater than in the general population
[2,4,5]. The higher incidence of post-transplantation CVD is
the result of an increase in the prevalence of traditional risk
factors such as diabetes mellitus (DM), hypertension, cigarette
smoking, and hyperlipidemia and accumulation of several
nontraditional risk factors associated with CVD after kidney
transplantation, such as acute rejection episodes and the use of
immunosuppressive drugs [2,46].lsevier Inc. All rights reserved.
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ion Proceedings, 47, 985e988 (2015)Therefore, the risk-prediction equations defined and vali-
dated for the general population underestimate CVD risk for
kidney transplant recipients because risk factors pertinent to
kidney transplantation patients are not included in those
equations [4,5].
Application of the CVD and mortality risk equations
specifically tailored for RTRs [3], could help clinicians to0041-1345/15
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Table 1. Characteristics of the Study Population
Variable All Patients (n ¼ 121)
Recipient age (SD), y 49.6  13.8
Recipient sex: Men, n (%)/Women, n (%) 72 (59.5%)/49 (40.5%)
Recipient race: white, n (%)/black, n (%) 120 (99.2%)/1 (0.8%)
Time on dialysis, mo (SD) 50.2  42
Dialysis modality before the transplantation: pre-emptive,
n (%)/hemodialysis, n (%)/peritoneal dialysis, n (%)
7 (5.8%)/101 (83.5%)/13 (10.7%)
Number of transplants: first transplant, n (%)/second or more, n (%) 116 (95.9%)/5 (4.1%)
Dialysis duration (SD), mo 105.4  73.5
Donor type: deceased, n (%)/living, n (%) 107 (88.4%)/14 (11.6%)
Immunosuppressive regimen: TAC þ MMF þ PDN, n (%) 53 (43.8%)
eGFR (SD), mL/min/1.73m2 52.0  15.2
Primary cause of kidney failure: unknown, n (%)/chronic
glomerulopathy, n (%)/hypertension, n (%)/ADPKD, n (%)/diabetes
mellitus, n (%)/other, n (%)
41 (33.9%)/32 (26.4%)/11 (9.1%)/10 (8.3%)/6 (5.0%)/21 (17.4%)
Lipid abnormalities 86 (71%)
Total cholesterol (>5.18 mmol/L), n (%) 42 (34.7%)
LDL cholesterol (>2.59 mmol/L), n (%) 69 (57%)
Triglycerides (>1.67 mmol/L), n (%) 42 (34.7%)
HDL cholesterol: _ < 1.04 mmol/L, n(%)/\ < 1.17 mmol/L, n(%) 7 (5.8%)/13 (10.7%)
BMI (SD) 26.2  4.0
25  BMI < 30 kg/m2, n(%) 57 (47.1%)
BMI  30 kg/m2, n (%) 18 (14.9%)
Smoking status: current or former, n (%) 30 (24.8%)
Abbreviations: TAC, tacrolimus; MMF, mycophenolate mofetil; PDN, prednisolone; eGFR, estimated glomerular filtration rate; ADPKD, autosomal dominant poly-
cystic kidney disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, body mass index (kg/m2).
986 GONÇALVES, VIEIRA, RESENDE ET ALrisk-stratify their patients, decision support, quality of care
assessment, and patients education [3,4].
The aims of this study were to characterize the cardiovas-
cular risk factors, calculate the 7-year risk for major adverse
cardiac events (MACE) and death, and determine the main
cardiovascular risk factors associated with increased likelihood
of MACE and death in an RTR population.
PATIENTS AND METHODS
Between November 2013 and January 2014, we collected detailed
clinical data from 121 RTRs with a functioning and stable graft for
longer than 6 months in follow-up programs at our institution.
Recipient data elements included age, gender, race, primary cause of
kidney failure, time on dialysis, dialysis modality before transplantation,
number of transplants, time functioning graft, smoking status (current,
former, or never) and medical story (medication, baseline CVD, DM,
hypertension). Donor data elements included donor (deceased or
living). Follow-up data included immunosuppressive regimen, physical
examination findings (anthropometric measures, systolic and diastolic
blood pressure) and laboratory variables (serum creatinine and lipid
values).
Racewas definedaswhite, black, or other.Hypertensionwas defined
by systolic blood pressure  130 mm Hg, diastolic 80 mm Hg [7] or
antihypertensive medication use. Diabetes was defined by the use of
insulin or oral hypoglycemic medications or patient history. Reference
values for total, low-density lipoprotein (LDL), and high-density lipo-
protein (HDL) cholesterol levels and hypertriglyceridemia were based
on the final report from the third report of the national cholesterol
education program expert panel on detection, evaluation, and treat-
ment of high blood cholesterol in adults [8]. Body mass index (BMI)
was calculatedusing the formula: weight (kg)/height (m)2. Classification
is according to the cut-off points of theWorld Health Organization [9].Estimated glomerular filtration rate (eGFR) was calculated using the
four-variable Modification of Diet in Renal Disease Study equation,
based on serum creatinine level, age, gender, and race [10]. MACEwas
defined as cardiac death, nonfatal myocardial infarction, or coronary
revascularization procedure [3].
The formula for 7-year MACE and mortality risk calculation for
RTRs [3] was used that is known as the Cardiovascular Risk
Calculator for Renal Transplant Recipients (http://www.medsci.
uu.se/forskning/Inflammation_och_autoimmunitet/Njurmedicin/
Projekt/risk-calculator/) [11].
Results were expressed as mean values  SD. Univariate analysis
was performed using the c2 test and Student t test for categorical and
continuous data, respectively. Variables were used in the logistic
regression model to estimate odds ratio (OR) for higher rate (>10%)
of 7-year MACE and death. All P values were two-tailed and a P
value < .05 was considered significant.RESULTS
Among 121 adult patients followed at our institution
(Table 1), 72 were males (59.5%) with a mean age of 49.6
13.8 years. Before transplantation, 101 patients (83.5%)
were on hemodialysis, 13 patients (10.7%) were on peri-
toneal dialysis, and 7 patients (5.8%) received a pre-
emptive kidney transplant. The mean dialysis duration
was 50.2  42 months (minimum, 0 mo; maximum,
189 mo). The mean time of the functioning graft was
105.4..73.5 months (minimum, 6 mo; maximum, 358 mo).
Recipients showed a mean eGFR of 52.0  15.2 mL/min/
1.73 m2.
The causes of renal failure were glomerulonephritis
(26%), hypertension/nephrosclerosis (9%), polycystic kidney
Table 2. Univariate Analysis of Variables for 7-Year Risk for
MACE*
Variables Risk <10% Risk 10% P
Age (y) 43.8  11.9 62.4  7.4 .000
Gender
Male 42 (34.7%) 30 (24.8%) .005
Female 41 (33.9%) 8 (6.6%)
Diabetes mellitus 4 (3.3%) 20 (16.5%) .000
Systolic blood pressure (mm Hg) 127.2  14.9 134.8  14.6 .01
Current or former smoking 13 (10.7%) 17 (14.0%) .001
Abbreviations: MACE, major adverse cardiac events; CVD, cardiovascular
disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
*Dialysis duration, time functioning graft, baseline CVD, body mass index,
estimated glomerular filtration rate, antihypertensive medications, total choles-
terol level, LDL cholesterol, HDL cholesterol and triglycerides, showed no sta-
tistical significance.
Table 3. Univariate Analysis of Variables for 7-Year Risk for
Death*
Variables Risk <10% Risk 10% P
Age (y) 39.8  10.3 61.0  7.0 .000
Gender
Male 30 (%) 42 (%) .002
Female 35 (%) 14 (%)
Diabetes mellitus 7 (%) 17 (%) .000
Systolic blood pressure (mm Hg) 125.4  14.5 134.5  14.5 .001
Current or former smoking 8 (10.7%) 22 (14.0%) .001
Antihypertensive medications
(number)
1.6  1.1 2.0  1.1 .041
Total cholesterol level (mmol/L) 4.59  0.94 5.14  0.94 .002
Abbreviations: CVD, cardiovascular disease; LDL, low-density lipoprotein;
HDL, high-density lipoprotein.
*Dialysis duration, time functioning graft, baseline CVD, body mass index,
estimated glomerular filtration rate, LDL cholesterol, HDL cholesterol and
Triglycerides, showed no statistical significance.
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and other (17%).
The prevalence of DM among our RTRs was 19.8%. In
this analysis, DM was a composite including type 1 and type
2 DM diagnosed before transplantation and new onset DM
after renal transplantation.
We found a high prevalence of hypertension among our
patients, with 86.8% of patients who had high blood
pressure or who received antihypertensive medication.
The prevalence of lipid abnormalities among our study
population was 71%. In more detail, 34.7% of patients had
high total cholesterol levels, 57% of patients had high LDL
cholesterol levels, 16.5% had low HDL cholesterol levels
(5.8% of men and 10.7% of women), and there was
hypertriglyceridemia in 34.7% of patients. Fifty-five
percent of the patients had been treated with statin. The
prevalence of cigarette smoking (current or former) among
our patients was 24.8%. High BMI was observed in 61.9%
of patients, including 57 (47.1%) who were overweight
(25  BMI < 30 kg/m2) and 18 (14.9%) who were obese
(BMI  30 kg/m2).
Using the Cardiovascular Risk Calculator for Renal
Transplant Recipients, the 7-year risk for MACE was less
than 10% in 83 (68.6%) patients, between 10% and 20% in
22 (18.2%) patients, and more than 20% in 16 (13.2%)
patients. The 7-year risk for death was less than 10% in 65
(53.7%) patients, between 10% and 20% in 25 (20.7%)
patients, and more than 20% in 31 (13.2%) patients.
Univariate analysis of variables for the 7-year risk for
MACE (Table 2) showed that older age (P <.0001), male
gender (P ¼ .005), DM (P < .0001), higher systolic blood
pressure (P ¼.01), and current or former smoking (P ¼
.001) were significant risk factors for the increased (>10%)
7-year risk for MACE. The logistic regression model
revealed that male gender (OR ¼ 8.14; P ¼ .032; 95%
confidence interval [CI], 1.193e55.546), age older than 55
years (OR ¼ 9.33; P ¼ .001; 95% CI, 2.439e35.717), DM
(OR ¼ 84.909; P < .0001; 95% CI, 10.627e678.407), and
current or former smoking (OR ¼ 9.481; P¼ .005; 95% CI,
1.996e45.047) were independent risk factors to predict a
higher risk of MACE (>10%). The same analysisconfirmed a lack of correlation of dialysis duration, time
of functioning graft, graft eGFR, BMI, number of antihy-
pertensive drugs, and total cholesterol.
Regarding the 7-year risk for death (Table 3), older age
(P < .0001), male gender (P ¼ .002), DM (P < .0001),
higher systolic blood pressure (P ¼ .01), higher number of
antihypertensive medications (P¼ .041), current or former
smoking (P ¼ .001), and higher total cholesterol level
(P ¼ .002) were significant risk factors for the increased
(>10%) 7-year risk for death. The logistic regression
model revealed that age older than 55 years (OR ¼
222.870; P < .0001; 95% CI, 25.464e1950.608) and current
or former smoking (OR ¼ 15.103; P ¼ .004; 95% CI,
2.366e96.408) were independent risk factors to predict a
higher risk of death (>10%). The same analysis confirmed
a lack of correlation of gender, dialysis duration, time of
functioning graft, DM, graft eGFR, BMI, number of
antihypertensive drugs, and total cholesterol.DISCUSSION
RTRs are at increased risk of cardiovascular complications
[2]. When compared with the general population, RTRs
show a 4-fold greater risk for CVD and a 2-fold higher risk
for death attributable to CVD [12].
Traditional risk factors for CVD, such as smoking, DM,
and hypercholesterolemia, are well known to increase the
risk of CVD [2]. In addition, there are specific trans-
plantation risk factors such as deceased donors [13], longer
duration of pretransplantation dialysis [5,14], and immu-
nosuppressive drugs [2,5,6]. Indeed, corticosteroids and
calcineurin inhibitors have a range of potential effects on
cardiovascular risk [5,6], including increases in the risk and
severity of hypertension, lipid abnormalities, and DM [2,6].
In our study, we characterized the cardiovascular risk factors
that were present in an RTR population. Our results show that
the prevalence of DM among our population of transplant
recipients was 19.8%, lower than in other populations of renal
transplantations [10], but much higher than the Framingham
988 GONÇALVES, VIEIRA, RESENDE ET ALHeart Study population (5.2% in males and 4.0% in females).
The prevalence of hypertension varies between 21% and 26%
among the general population, compared with 86.8% in our
population of RTRs, overlapping with other existing studies in
kidney transplantation (70% to 85%) [2]. Interestingly, the
prevalence of lipid abnormalities among our RTRs was very
high (71%) compared with general population. However, the
prevalence in our population overlaps with other populations
ofRTRs [2].Despite the prevalence of lipid abnormalities, only
55% of patients are treated with statins. Comparing our results
with other studies [2,5], it was evident that transplant recipients
have several traditional risk factors (DM, hypertension, total
cholesterol, LDL cholesterol, HDL cholesterol, triglycerides),
with studies showing that these risk factors can predict the
incidence of CVD [2,5].
Another aim of our study was to calculate the 7-year risk
for MACE and death using a risk calculator specifically
tailored for RTRs [3]. We use this calculator because, unlike
calculators developed for the general population which do
not include risk factors pertinent to RTRs, this prediction
equation was drawn for assessment of cardiovascular risk and
mortality risk among RTRs [3].
The prediction calculator [3,11] showed that 31.4% and
13.2% of our population had an estimated probability of
7-year MACE greater than 10% and 20%, respectively.
The mortality risk calculation in our population [3,11]
showed that 46.3% and 25.6% of our population had an
estimated probability of 7-year death of more than 10%
and 20%, respectively. These results support the concept
that RTRs have increased risk of cardiovascular compli-
cations and death. Application of the individualized and
accurate prediction equations allows the clinical risk
stratification of our patients.
Which factors most influence the increased risk CVD and
death must be considered. In our study, we found a statistically
significant relationship between increased cardiovascular risk
and age, male gender, DM, systolic blood pressure, and current
or former smoking. We also found a statistically significant
relationship between the 7-year risk of death and age, male
gender, DM, higher levels of systolic blood pressure, more
antihypertensive medications, current or former smoking, and
total cholesterol level. Our findings also complement the Car-
diovascular Risk Calculator for Renal Transplant Recipients
because new risk markers are constantly being proposed and
are likely to be incorporated into risk prediction algorithms [3].
To our knowledge, this is the first application of the
prediction of the 7-year risk of MACE and 7-year risk of
death to an entire population of RTRs. More studies are
essential for comparing risk between populations of RTRs
and establish the desirable lower risk for these populations.
The application of this calculator individually for each
patient works not only as an educational tool in motivatingthese patients, but also help physicians to stratify patients
and to take appropriate measures to reduce individual
cardiovascular risk or to diagnose and treat non-
symptomatic CVD, reducing the risk of MACE and death
in RTRs.
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